Deborah Robson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Deborah Robson has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Ann McNeill
Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
9 shared publications - Richard Gray
School of Nursing and Midwifery, La Trobe University, Melbourne, VIC 3086, Australia
6 shared publications - Leonie Sarah Brose
National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London London UK
5 shared publications - Allan Tyler
London South Bank University
3 shared publications - Allison Ford
Institute for Social Marketing and Health, University of Stirling, Stirling, UK
3 shared publications - Gilda Spaducci
Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
3 shared publications
Latest Publications
- Open Access
Interventions to change vaping harm perceptions and associations between harm perceptions and vaping and smoking behaviours: A systematic review
Aims: To synthesize and describe the evidence from among young people and adults to assess: (i) what interventions have been effective in changing vaping harm perceptions; and (ii) to what extent vaping harm perceptions predict any changes in vaping and smoking behaviours. Methods: Systematic review searching five databases (Embase, PsycINFO, Medline, CINAHL, Scopus) from January 2007 to January 2023. Eligible studies reported quantitative data with >1 time point among young people (sample majority aged <18 years) or adults (sample majority aged ≥18 years). Interventions were considered if they communicated vaping harms, categorized as relative (vaping vs smoking) or absolute (vaping vs not vaping). Outcomes were changes in: (i) vaping (absolute, relative) or nicotine harm perceptions; (ii) vaping or smoking behaviours. Evidence was synthesized narratively. Results: Eighty‐five articles were included, of which 46 assessed interventions to change vaping harm perceptions and 39 assessed associations between harm perceptions and subsequent vaping/smoking behaviours. All studies among young people and most among adults were from the USA. Interventions aimed at young people typically communicated that vaping and nicotine are harmful/addictive (absolute harms), often in the form of educational programmes and media campaigns. Interventions aimed at adults typically communicated that vaping is harmful but less harmful than smoking (relative harms), often via written materials and educational workshops. In addition to methodological and analytical heterogeneity, risk of bias was high; hence findings should be interpreted with caution. Generally, interventions appeared to be effective in changing perceptions that reflected the intervention content among young people (12/14 studies) and adults (24/32 studies), at least in the short‐term (38/46 studies only assessed the outcome pre‐ and immediately post‐intervention). Interventions communicating that vaping is harmful and addictive (absolute harms) increased perceptions that vaping is harmful and addictive among young people (12/14) and adults (16/23 studies) and also increased the misperception that vaping is as harmful as smoking (relative harm) among young people (2/2 studies) and adults (5/8 studies). There was also some evidence that both absolute and relative harm perceptions predicted vaping and smoking behaviours, such that perceiving vaping as harmful deterred vaping among both young people (8/9 studies) and adults (4/7 studies), while misperceiving vaping as equally/more harmful than smoking prevented adults from quitting smoking (5/6 studies). Conclusions: Interventions to change vaping harm perceptions appear to be effective. Vaping harm perceptions appear to predict vaping and smoking behaviours.
Open AccessInterventions to change vaping harm perceptions and associations between harm perceptions and vaping and smoking behaviours: A systematic review
Aims: To synthesize and describe the evidence from among young people and adults to assess: (i) what interventions have been effective in changing vaping harm perceptions; and (ii) to what extent vaping harm perceptions predict any changes in vaping and smoking behaviours. Methods: Systematic review searching five databases (Embase, PsycINFO, Medline, CINAHL, Scopus) from January 2007 to January 2023. Eligible studies reported quantitative data with >1 time point among young people (sample majority aged <18 years) or adults (sample majority aged ≥18 years). Interventions were considered if they communicated vaping harms, categorized as relative (vaping vs smoking) or absolute (vaping vs not vaping). Outcomes were changes in: (i) vaping (absolute, relative) or nicotine harm perceptions; (ii) vaping or smoking behaviours. Evidence was synthesized narratively. Results: Eighty‐five articles were included, of which 46 assessed interventions to change vaping harm perceptions and 39 assessed associations between harm perceptions and subsequent vaping/smoking behaviours. All studies among young people and most among adults were from the USA. Interventions aimed at young people typically communicated that vaping and nicotine are harmful/addictive (absolute harms), often in the form of educational programmes and media campaigns. Interventions aimed at adults typically communicated that vaping is harmful but less harmful than smoking (relative harms), often via written materials and educational workshops. In addition to methodological and analytical heterogeneity, risk of bias was high; hence findings should be interpreted with caution. Generally, interventions appeared to be effective in changing perceptions that reflected the intervention content among young people (12/14 studies) and adults (24/32 studies), at least in the short‐term (38/46 studies only assessed the outcome pre‐ and immediately post‐intervention). Interventions communicating that vaping is harmful and addictive (absolute harms) increased perceptions that vaping is harmful and addictive among young people (12/14) and adults (16/23 studies) and also increased the misperception that vaping is as harmful as smoking (relative harm) among young people (2/2 studies) and adults (5/8 studies). There was also some evidence that both absolute and relative harm perceptions predicted vaping and smoking behaviours, such that perceiving vaping as harmful deterred vaping among both young people (8/9 studies) and adults (4/7 studies), while misperceiving vaping as equally/more harmful than smoking prevented adults from quitting smoking (5/6 studies). Conclusions: Interventions to change vaping harm perceptions appear to be effective. Vaping harm perceptions appear to predict vaping and smoking behaviours.
- Open Access
- 7 April 2025
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 21, 100604
Psychological distress, tobacco smoking and alcohol use: A population survey in Great Britain
- 7 April 2025
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 21, 100604
Open AccessPsychological distress, tobacco smoking and alcohol use: A population survey in Great Britain
- Open Access
Exploring how an e-cigarette intervention influenced tobacco smoking behaviour in people accessing homelessness services: findings from the SCeTCH trial process evaluation
Background: Smoking prevalence among people experiencing homelessness is high. This study explored the factors which influenced potential smoking abstinence among participants receiving an e-cigarette (EC) intervention within the Smoking Cessation Trial in Centres for Homelessness (SCeTCH) across Great Britian. Methods: Using the Capability Opportunity Motivation – Behaviour (COM-B) model, hypothesised and emerging mediators were explored quantitatively via measures in baseline and follow-up questionnaires (n=239) and qualitatively via interviews with homelessness centre staff (n=16) and participants (n=31) who received an EC starter pack and 4-week e-liquid supply. We purposively sampled 8 centres for interviews, representing varied regions and participant vaping/smoking and sociodemographic status. Quantitative measures were analysed descriptively. Qualitative data were analysed thematically. Data from the two approaches were mapped onto the COM-B for combined analysis and reporting. Results: After receiving the intervention, participants demonstrated high capability to use EC and appreciation of EC for harm reduction. Some participants reported dissatisfaction with vaping. Opportunity for behaviour change was strengthened by perceived acceptability to vape and social support beyond the centre but hindered by a smoking culture and perceived lack of staff support. Motivation was enhanced by EC efficacy belief, pride from cutting down, and financial benefits of vaping, but negatively impacted by challenging personal circumstances. Conclusion: For people accessing homelessness support centres, smoking abstinence remains challenging. More intensive support and a variety of approaches to support smoking cessation, particularly those which address the psychosocial factors which hinder smoking abstinence, may be required. Future research should focus on how this can be achieved.
Open AccessExploring how an e-cigarette intervention influenced tobacco smoking behaviour in people accessing homelessness services: findings from the SCeTCH trial process evaluation
Background: Smoking prevalence among people experiencing homelessness is high. This study explored the factors which influenced potential smoking abstinence among participants receiving an e-cigarette (EC) intervention within the Smoking Cessation Trial in Centres for Homelessness (SCeTCH) across Great Britian. Methods: Using the Capability Opportunity Motivation – Behaviour (COM-B) model, hypothesised and emerging mediators were explored quantitatively via measures in baseline and follow-up questionnaires (n=239) and qualitatively via interviews with homelessness centre staff (n=16) and participants (n=31) who received an EC starter pack and 4-week e-liquid supply. We purposively sampled 8 centres for interviews, representing varied regions and participant vaping/smoking and sociodemographic status. Quantitative measures were analysed descriptively. Qualitative data were analysed thematically. Data from the two approaches were mapped onto the COM-B for combined analysis and reporting. Results: After receiving the intervention, participants demonstrated high capability to use EC and appreciation of EC for harm reduction. Some participants reported dissatisfaction with vaping. Opportunity for behaviour change was strengthened by perceived acceptability to vape and social support beyond the centre but hindered by a smoking culture and perceived lack of staff support. Motivation was enhanced by EC efficacy belief, pride from cutting down, and financial benefits of vaping, but negatively impacted by challenging personal circumstances. Conclusion: For people accessing homelessness support centres, smoking abstinence remains challenging. More intensive support and a variety of approaches to support smoking cessation, particularly those which address the psychosocial factors which hinder smoking abstinence, may be required. Future research should focus on how this can be achieved.
- Open Access
Harm perceptions across vaping product features: An on‐line cross‐sectional survey of adults who smoke and/or vape in the United Kingdom
Background and aims: Vaping products are diverse with a wide variety of features, and popular products change rapidly. This study examined the features and types of vaping products that people who smoke and/or vape perceive contribute to the health harms of vaping.Design, setting and participants: This was a cross‐sectional survey co‐designed with adults who smoked/vaped and pre‐registered. An on‐line survey (November 2022) was used of a convenience sample of adults in the United Kingdom who smoked and/or vaped (n = 494).Measurements: As primary outcomes, respondents were asked to select any of 15 vaping product features they perceived might have any effect on the health harms of vaping (for each: selected, not selected). Independent variables were smoking/vaping status (smoke and vape; vape, formerly smoked; vape, never regularly smoked; smoke, do not currently vape); relative vaping harm perceptions [less harmful than smoking (accurate), equally/more harmful than smoking or do not know/refused (other)]. Binary logistic regressions were used to compare outcomes by current vaping/smoking status and relative harm perceptions, adjusting for age and sex.Findings: Most people (54.7%) selected between one and three features. The most frequently selected were nicotine concentration (62.2%) and amount of e‐liquid consumed (59.1%), followed by nicotine type (e.g. salt or freebase; 33.0%), source/purchase location (25.3%), flavours (24.7%), temperature to heat e‐liquid (21.1%), heat produced by device (20.9%), e‐liquid brand (20.9%), amount of emissions (18.6%), device type (e.g. disposable, pod, tank; 17.2%), material of tank (17.0%), power/wattage (13.0%), device brand (8.1%), device size (4.1%) and device weight (2.4%). Higher nicotine concentrations, more e‐liquid and salt (versus freebase) nicotine were perceived to confer greater harms. Disposables were perceived as slightly more harmful than reusable devices. There were few differences by current vaping/smoking status and between those with accurate (versus other) harm perceptions of vaping relative to smoking (P > 0.05 for most contrasts, adjusting for age and sex).Conclusions: Certain features and types of vaping products [higher nicotine concentrations, more e‐liquid consumed and salt (versus freebase) nicotine] were perceived to confer greater health harms among a sample of UK adults who smoked and/or vaped. Findings are consistent with pervasive misperceptions that nicotine is a major cause of harm, although e‐liquid volume is likely to contribute to harms.
Open AccessHarm perceptions across vaping product features: An on‐line cross‐sectional survey of adults who smoke and/or vape in the United Kingdom
Background and aims: Vaping products are diverse with a wide variety of features, and popular products change rapidly. This study examined the features and types of vaping products that people who smoke and/or vape perceive contribute to the health harms of vaping.Design, setting and participants: This was a cross‐sectional survey co‐designed with adults who smoked/vaped and pre‐registered. An on‐line survey (November 2022) was used of a convenience sample of adults in the United Kingdom who smoked and/or vaped (n = 494).Measurements: As primary outcomes, respondents were asked to select any of 15 vaping product features they perceived might have any effect on the health harms of vaping (for each: selected, not selected). Independent variables were smoking/vaping status (smoke and vape; vape, formerly smoked; vape, never regularly smoked; smoke, do not currently vape); relative vaping harm perceptions [less harmful than smoking (accurate), equally/more harmful than smoking or do not know/refused (other)]. Binary logistic regressions were used to compare outcomes by current vaping/smoking status and relative harm perceptions, adjusting for age and sex.Findings: Most people (54.7%) selected between one and three features. The most frequently selected were nicotine concentration (62.2%) and amount of e‐liquid consumed (59.1%), followed by nicotine type (e.g. salt or freebase; 33.0%), source/purchase location (25.3%), flavours (24.7%), temperature to heat e‐liquid (21.1%), heat produced by device (20.9%), e‐liquid brand (20.9%), amount of emissions (18.6%), device type (e.g. disposable, pod, tank; 17.2%), material of tank (17.0%), power/wattage (13.0%), device brand (8.1%), device size (4.1%) and device weight (2.4%). Higher nicotine concentrations, more e‐liquid and salt (versus freebase) nicotine were perceived to confer greater harms. Disposables were perceived as slightly more harmful than reusable devices. There were few differences by current vaping/smoking status and between those with accurate (versus other) harm perceptions of vaping relative to smoking (P > 0.05 for most contrasts, adjusting for age and sex).Conclusions: Certain features and types of vaping products [higher nicotine concentrations, more e‐liquid consumed and salt (versus freebase) nicotine] were perceived to confer greater health harms among a sample of UK adults who smoked and/or vaped. Findings are consistent with pervasive misperceptions that nicotine is a major cause of harm, although e‐liquid volume is likely to contribute to harms.
- Open Access
Pattern and prevalence of vaping nicotine and non-nicotine drugs in the United Kingdom: a cross-sectional study
Objectives Electronic vaping devices are being used to consume nicotine and non-nicotine psychoactive drugs. We aimed to determine the pattern and prevalence of using vaping devices for nicotine and/or non-nicotine drug administration in the United Kingdom and how these differ by drug type and individual sociodemographic characteristics. We explored reasons for vaping onset and continuation. Design An online cross-sectional survey Participants A convenience sample of adults (aged ≥18 years) in the UK. Primary and secondary outcome measures The primary outcome was prevalence of current use (within the last 30 days) of a vaping device to administer either nicotine or 18 types of non-nicotine drugs. We additionally evaluated reasons for onset and continuation of vaping. Sociodemographic characteristics were compared between the UK general population using census data and those vaping non-nicotine drugs. Results We recruited 4027 participants of whom 1637 (40.7%) had ever used an electronic vaping device; 1495 (37.1%) had ever vaped nicotine and 593 (14.7%) had ever vaped a non-nicotine drug. Overall, 574 (14.3%) currently vaped nicotine and 74 (1.8%) currently vaped a non-nicotine drug. The most common currently vaped non-nicotine drug was cannabis (n=58, 1.4%). For nicotine, people’s modal reasons to start and continue vaping was to quit smoking tobacco. For almost all other drugs, people’s modal reason to start vaping was curiosity and to continue was enjoyment. Compared with the general population, the population who had ever vaped a non-nicotine drug were significantly younger, had more disabilities and fewer identified as white, female, heterosexual or religious. Conclusions A non-trivial number of people report current use and ever use of an electronic vaping device for non-nicotine drug administration. As vaping technology advances and drug consumption changes, understanding patterns of use and associated behaviours are likely to be increasingly important to both users and healthcare professionals.
Open AccessPattern and prevalence of vaping nicotine and non-nicotine drugs in the United Kingdom: a cross-sectional study
Objectives Electronic vaping devices are being used to consume nicotine and non-nicotine psychoactive drugs. We aimed to determine the pattern and prevalence of using vaping devices for nicotine and/or non-nicotine drug administration in the United Kingdom and how these differ by drug type and individual sociodemographic characteristics. We explored reasons for vaping onset and continuation. Design An online cross-sectional survey Participants A convenience sample of adults (aged ≥18 years) in the UK. Primary and secondary outcome measures The primary outcome was prevalence of current use (within the last 30 days) of a vaping device to administer either nicotine or 18 types of non-nicotine drugs. We additionally evaluated reasons for onset and continuation of vaping. Sociodemographic characteristics were compared between the UK general population using census data and those vaping non-nicotine drugs. Results We recruited 4027 participants of whom 1637 (40.7%) had ever used an electronic vaping device; 1495 (37.1%) had ever vaped nicotine and 593 (14.7%) had ever vaped a non-nicotine drug. Overall, 574 (14.3%) currently vaped nicotine and 74 (1.8%) currently vaped a non-nicotine drug. The most common currently vaped non-nicotine drug was cannabis (n=58, 1.4%). For nicotine, people’s modal reasons to start and continue vaping was to quit smoking tobacco. For almost all other drugs, people’s modal reason to start vaping was curiosity and to continue was enjoyment. Compared with the general population, the population who had ever vaped a non-nicotine drug were significantly younger, had more disabilities and fewer identified as white, female, heterosexual or religious. Conclusions A non-trivial number of people report current use and ever use of an electronic vaping device for non-nicotine drug administration. As vaping technology advances and drug consumption changes, understanding patterns of use and associated behaviours are likely to be increasingly important to both users and healthcare professionals.
- Open Access
Evaluating the effectiveness of e‐cigarettes compared with usual care for smoking cessation when offered to smokers at homeless centres: protocol for a multi‐centre cluster‐randomized controlled trial in Great Britain
Background and aims: Smoking is extremely common among adults experiencing homelessness, but there is lack of evidence for treatment efficacy. E‐cigarettes are an effective quitting aid, but they have not been widely tested in smokers with complex health and social needs. Here we build upon our cluster feasibility trial and evaluate the offer of an e‐cigarette or usual care to smokers accessing a homeless centre.Design, Setting and Participants: Multi‐centre two‐arm cluster‐randomized controlled trial with mixed‐method embedded process and economic evaluation in homeless centres in England, Scotland and Wales. Adult smokers (18+ years; n = 480) accessing homeless centres and who are known to centre staff and willing to consent.Intervention and Comparator: Clusters (n = 32) will be randomized to either an e‐cigarette starter pack with weekly allocations of nicotine containing e‐liquid for 4 weeks [choice of flavours (menthol, fruit and tobacco) and strengths 12 mg/ml and 18 mg/ml] or the usual care intervention, which comprises very brief advice and a leaflet signposting to the local stop smoking service.Measurements: The primary outcome is 24‐week sustained carbon monoxide‐validated smoking cessation (Russell Standard defined, intention‐to‐treat analysis). Secondary outcomes: (i) 50% smoking reduction (cigarettes per day) from baseline to 24 weeks; (ii) 7‐day point prevalence quit rates at 4‐, 12‐ and 24‐week follow‐up; (iii) changes in risky smoking practices (e.g. sharing cigarettes, smoking discarded cigarettes) from baseline to 4, 12 and 24 weeks; (iv) cost‐effectiveness of the intervention; and (v) fidelity of intervention implementation; mechanisms of change; contextual influences and sustainability.Conclusions: This is the first study, to our knowledge, to randomly assign smokers experiencing homelessness to an e‐cigarette and usual care intervention to measure smoking abstinence with embedded process and economic evaluations. If effective, its results will be used to inform the larger‐scale implementation of offering e‐cigarettes throughout homeless centres to aid smoking cessation.
Open AccessEvaluating the effectiveness of e‐cigarettes compared with usual care for smoking cessation when offered to smokers at homeless centres: protocol for a multi‐centre cluster‐randomized controlled trial in Great Britain
Background and aims: Smoking is extremely common among adults experiencing homelessness, but there is lack of evidence for treatment efficacy. E‐cigarettes are an effective quitting aid, but they have not been widely tested in smokers with complex health and social needs. Here we build upon our cluster feasibility trial and evaluate the offer of an e‐cigarette or usual care to smokers accessing a homeless centre.Design, Setting and Participants: Multi‐centre two‐arm cluster‐randomized controlled trial with mixed‐method embedded process and economic evaluation in homeless centres in England, Scotland and Wales. Adult smokers (18+ years; n = 480) accessing homeless centres and who are known to centre staff and willing to consent.Intervention and Comparator: Clusters (n = 32) will be randomized to either an e‐cigarette starter pack with weekly allocations of nicotine containing e‐liquid for 4 weeks [choice of flavours (menthol, fruit and tobacco) and strengths 12 mg/ml and 18 mg/ml] or the usual care intervention, which comprises very brief advice and a leaflet signposting to the local stop smoking service.Measurements: The primary outcome is 24‐week sustained carbon monoxide‐validated smoking cessation (Russell Standard defined, intention‐to‐treat analysis). Secondary outcomes: (i) 50% smoking reduction (cigarettes per day) from baseline to 24 weeks; (ii) 7‐day point prevalence quit rates at 4‐, 12‐ and 24‐week follow‐up; (iii) changes in risky smoking practices (e.g. sharing cigarettes, smoking discarded cigarettes) from baseline to 4, 12 and 24 weeks; (iv) cost‐effectiveness of the intervention; and (v) fidelity of intervention implementation; mechanisms of change; contextual influences and sustainability.Conclusions: This is the first study, to our knowledge, to randomly assign smokers experiencing homelessness to an e‐cigarette and usual care intervention to measure smoking abstinence with embedded process and economic evaluations. If effective, its results will be used to inform the larger‐scale implementation of offering e‐cigarettes throughout homeless centres to aid smoking cessation.
- Open Access
Harm perceptions of nicotine‐containing products and associated sources of information in UK adults with and without mental ill health: A cross‐sectional survey
Background and Aims: People with mental ill health are more likely to smoke and experience smoking‐related harm than those without. Switching from combustible tobacco to lower‐risk nicotine‐containing products may be of benefit; however, misperceptions of harm may prevent their use. We aimed to assess, among adults with and without mental ill health, (1) perceptions of harm from nicotine and relative harm and addictiveness of different nicotine‐containing products and (2) sources of information associated with harm perceptions. Design: Cross‐sectional study. Setting and Participants: On‐line survey of adults ( n = 3400) who smoke cigarettes and/or use e‐cigarettes, or have recently stopped, in the United Kingdom. Measurements: Outcomes: harm perceptions of nicotine; relative perceived harm and addictiveness of different nicotine‐containing products; sources of information for harm perceptions of nicotine, cigarette smoking and e‐cigarettes. Demographics: sex, age, education, ethnic group and region. Other measures: self‐reported smoking, vaping and mental health status. Analyses: frequencies and logistic regressions adjusting for demographic/other measures. Findings: Among those with serious mental distress (versus no/low mental distress): 9.6% [13.9%, adjusted odds ratio (aOR) = 0.69, 95% confidence interval (CI) = 0.50–0.97] correctly identified that none/a very small amount of the health risks of smoking cigarettes come from nicotine; 41.7% (53.5%, aOR = 0.67, 95% CI = 0.54–0.84) perceived e‐cigarettes and 53.2% (70.3%, aOR = 0.62, 95% CI = 0.50–0.77) perceived nicotine replacement therapy to be less harmful than cigarettes; and 42.1% (51.3%, aOR = 0.77, 95% CI = 0.62–0.95) perceived e‐cigarettes as being less likely than cigarettes to cause cancer, 35.4% (45.5%, aOR = 0.71, 95% CI = 0.57–0.88) heart attacks and 34.9% (42.3%, aOR = 0.80, 95% CI = 0.64–0.99) lung problems. The most popular sources of information for cigarette smoking, e‐cigarettes and nicotine were scientific experts’ opinions and media reports, with little variation by mental distress. Conclusions: Among adults with a history of tobacco and/or e‐cigarette use, those with serious mental distress appear to have less accurate harm perceptions of nicotine and nicotine‐containing products than those with no/low distress, despite reporting similar sources of information.
Open AccessHarm perceptions of nicotine‐containing products and associated sources of information in UK adults with and without mental ill health: A cross‐sectional survey
Background and Aims: People with mental ill health are more likely to smoke and experience smoking‐related harm than those without. Switching from combustible tobacco to lower‐risk nicotine‐containing products may be of benefit; however, misperceptions of harm may prevent their use. We aimed to assess, among adults with and without mental ill health, (1) perceptions of harm from nicotine and relative harm and addictiveness of different nicotine‐containing products and (2) sources of information associated with harm perceptions. Design: Cross‐sectional study. Setting and Participants: On‐line survey of adults ( n = 3400) who smoke cigarettes and/or use e‐cigarettes, or have recently stopped, in the United Kingdom. Measurements: Outcomes: harm perceptions of nicotine; relative perceived harm and addictiveness of different nicotine‐containing products; sources of information for harm perceptions of nicotine, cigarette smoking and e‐cigarettes. Demographics: sex, age, education, ethnic group and region. Other measures: self‐reported smoking, vaping and mental health status. Analyses: frequencies and logistic regressions adjusting for demographic/other measures. Findings: Among those with serious mental distress (versus no/low mental distress): 9.6% [13.9%, adjusted odds ratio (aOR) = 0.69, 95% confidence interval (CI) = 0.50–0.97] correctly identified that none/a very small amount of the health risks of smoking cigarettes come from nicotine; 41.7% (53.5%, aOR = 0.67, 95% CI = 0.54–0.84) perceived e‐cigarettes and 53.2% (70.3%, aOR = 0.62, 95% CI = 0.50–0.77) perceived nicotine replacement therapy to be less harmful than cigarettes; and 42.1% (51.3%, aOR = 0.77, 95% CI = 0.62–0.95) perceived e‐cigarettes as being less likely than cigarettes to cause cancer, 35.4% (45.5%, aOR = 0.71, 95% CI = 0.57–0.88) heart attacks and 34.9% (42.3%, aOR = 0.80, 95% CI = 0.64–0.99) lung problems. The most popular sources of information for cigarette smoking, e‐cigarettes and nicotine were scientific experts’ opinions and media reports, with little variation by mental distress. Conclusions: Among adults with a history of tobacco and/or e‐cigarette use, those with serious mental distress appear to have less accurate harm perceptions of nicotine and nicotine‐containing products than those with no/low distress, despite reporting similar sources of information.
- Open Access
- 1 May 2021
- Published by National Institute for Health and Care Research in Public Health Research
- Vol. 9 (7) , 1-82
Exploring the uptake and use of electronic cigarettes provided to smokers accessing homeless centres: a four-centre cluster feasibility trial
Background: Smoking prevalence is extremely high in adults experiencing homelessness, and there is little evidence regarding which cessation interventions work best. This study explored the feasibility of providing free electronic cigarette starter kits to smokers accessing homeless centres in the UK. Objectives: Seven key objectives were examined to inform a future trial: (1) assess willingness of smokers to participate in the study to estimate recruitment rates; (2) assess participant retention in the intervention and control arms; (3) examine the perceived value of the intervention, facilitators of and barriers to engagement, and influence of local context; (4) assess service providers’ capacity to support the study and the type of information and training required; (5) assess the potential efficacy of supplying free electronic cigarette starter kits; (6) explore the feasibility of collecting data on contacts with health-care services as an input to a main economic evaluation; and (7) estimate the cost of providing the intervention and usual care. Design: A prospective cohort four-centre pragmatic cluster feasibility study with embedded qualitative process evaluation. Setting: Four homeless centres. Two residential units in London, England. One day centre in Northampton, England. One day centre in Edinburgh, Scotland. Intervention: In the intervention arm, a single refillable electronic cigarette was provided together with e-liquid, which was provided once per week for 4 weeks (choice of three flavours: fruit, menthol or tobacco; two nicotine strengths: 12 or 18 mg/ml). There was written information on electronic cigarette use and support. In the usual-care arm, written information on quitting smoking (adapted from NHS Choices) and signposting to the local stop smoking service were provided. Results: Fifty-two per cent of eligible participants invited to take part in the study were successfully recruited (56% in the electronic cigarette arm; 50.5% in the usual-care arm; total n = 80). Retention rates were 75%, 63% and 59% at 4, 12 and 24 weeks, respectively. The qualitative component found that perceived value of the intervention was high. Barriers were participants’ personal difficulties and cannabis use. Facilitators were participants’ desire to change, free electronic cigarettes and social dynamics. Staff capacity to support the study was generally good. Carbon monoxide-validated sustained abstinence rates at 24 weeks were 6.25% (3/48) in the electronic cigarette arm compared with 0% (0/32) in the usual-care arm (intention to treat). Almost all participants present at follow-up visits completed measures needed for input into an economic evaluation, although information about staff time to support usual care could not be gathered. The cost of providing the electronic cigarette intervention was estimated at £114.42 per person. An estimated cost could not be calculated for usual care. Limitations: Clusters could not be fully randomised because of a lack of centre readiness. The originally specified recruitment target was not achieved and recruitment was particularly difficult in residential centres. Blinding was not possible for the measurement of outcomes. Staff time supporting usual care could not be collected. Conclusions: The study was associated with reasonable recruitment and retention rates and promising acceptability in the electronic cigarette arm. Data required for full cost-effectiveness evaluation in the electronic cigarette arm could be collected, but some data were not available in the usual-care arm. Future work: Future research should focus on several key issues to help design optimal studies and interventions with this population, including which types of centres the intervention works best in, how best to retain participants in the study, how to help staff to deliver the intervention, and how best to record staff treatment time given the demands on their time. Trial registration: Current Controlled Trials ISRCTN14140672; the protocol was registered as researchregistry4346. Funding: This project was funded by the National Institute for Health Research (NIHR) Public Health Research programme and will be published in full in Public Health Research; Vol. 9, No. 7. See the NIHR Journals Library website for further project information.
- 1 May 2021
- Published by National Institute for Health and Care Research in Public Health Research
- Vol. 9 (7) , 1-82
Open AccessExploring the uptake and use of electronic cigarettes provided to smokers accessing homeless centres: a four-centre cluster feasibility trial
Background: Smoking prevalence is extremely high in adults experiencing homelessness, and there is little evidence regarding which cessation interventions work best. This study explored the feasibility of providing free electronic cigarette starter kits to smokers accessing homeless centres in the UK. Objectives: Seven key objectives were examined to inform a future trial: (1) assess willingness of smokers to participate in the study to estimate recruitment rates; (2) assess participant retention in the intervention and control arms; (3) examine the perceived value of the intervention, facilitators of and barriers to engagement, and influence of local context; (4) assess service providers’ capacity to support the study and the type of information and training required; (5) assess the potential efficacy of supplying free electronic cigarette starter kits; (6) explore the feasibility of collecting data on contacts with health-care services as an input to a main economic evaluation; and (7) estimate the cost of providing the intervention and usual care. Design: A prospective cohort four-centre pragmatic cluster feasibility study with embedded qualitative process evaluation. Setting: Four homeless centres. Two residential units in London, England. One day centre in Northampton, England. One day centre in Edinburgh, Scotland. Intervention: In the intervention arm, a single refillable electronic cigarette was provided together with e-liquid, which was provided once per week for 4 weeks (choice of three flavours: fruit, menthol or tobacco; two nicotine strengths: 12 or 18 mg/ml). There was written information on electronic cigarette use and support. In the usual-care arm, written information on quitting smoking (adapted from NHS Choices) and signposting to the local stop smoking service were provided. Results: Fifty-two per cent of eligible participants invited to take part in the study were successfully recruited (56% in the electronic cigarette arm; 50.5% in the usual-care arm; total n = 80). Retention rates were 75%, 63% and 59% at 4, 12 and 24 weeks, respectively. The qualitative component found that perceived value of the intervention was high. Barriers were participants’ personal difficulties and cannabis use. Facilitators were participants’ desire to change, free electronic cigarettes and social dynamics. Staff capacity to support the study was generally good. Carbon monoxide-validated sustained abstinence rates at 24 weeks were 6.25% (3/48) in the electronic cigarette arm compared with 0% (0/32) in the usual-care arm (intention to treat). Almost all participants present at follow-up visits completed measures needed for input into an economic evaluation, although information about staff time to support usual care could not be gathered. The cost of providing the electronic cigarette intervention was estimated at £114.42 per person. An estimated cost could not be calculated for usual care. Limitations: Clusters could not be fully randomised because of a lack of centre readiness. The originally specified recruitment target was not achieved and recruitment was particularly difficult in residential centres. Blinding was not possible for the measurement of outcomes. Staff time supporting usual care could not be collected. Conclusions: The study was associated with reasonable recruitment and retention rates and promising acceptability in the electronic cigarette arm. Data required for full cost-effectiveness evaluation in the electronic cigarette arm could be collected, but some data were not available in the usual-care arm. Future work: Future research should focus on several key issues to help design optimal studies and interventions with this population, including which types of centres the intervention works best in, how best to retain participants in the study, how to help staff to deliver the intervention, and how best to record staff treatment time given the demands on their time. Trial registration: Current Controlled Trials ISRCTN14140672; the protocol was registered as researchregistry4346. Funding: This project was funded by the National Institute for Health Research (NIHR) Public Health Research programme and will be published in full in Public Health Research; Vol. 9, No. 7. See the NIHR Journals Library website for further project information.
- Open Access
Drug‐related deaths associated with vaping product use in the United Kingdom
Background and Aims: Between March 2019 and February 2020 there was an outbreak of acute lung injury associated with vaping tetrahydrocannabinol (THC), contaminated with vitamin E acetate, in the United States. To date, there has been no comprehensive study of drug‐related deaths associated with vaping products in the United Kingdom. We aimed to identify any trends in drug‐related deaths associated with vaping product use in the United Kingdom. Methods: We retrospectively identified any deaths associated with the use of vaping products reported to the UK National Programme on Substance Abuse Deaths (NPSAD). This contains voluntarily reported information from UK Coroners on more than 42 000 deaths related to psychoactive drugs, other than nicotine or caffeine, which occurred between 1997 and 2020. Results: Two drug‐related deaths were reported which were associated with vaping products, one person having died in 2017 and one in 2018. Both decedents were men currently serving prison sentences in England and were aged 26 and 42 years at the time of death. Both deaths were associated with recent use of Synthetic Cannabinoid Receptor Agonists (SCRAs), with no other substances found to be implicated in death. No details regarding the type of vaping products were available. Conclusions: In a UK sample (1997 to 2020) of 42 000 deaths related to psychoactive drugs other than nicotine or caffeine, only two deaths were associated with vaping products, and those involved use of synthetic cannabinoid receptor agonists.
Open AccessDrug‐related deaths associated with vaping product use in the United Kingdom
Background and Aims: Between March 2019 and February 2020 there was an outbreak of acute lung injury associated with vaping tetrahydrocannabinol (THC), contaminated with vitamin E acetate, in the United States. To date, there has been no comprehensive study of drug‐related deaths associated with vaping products in the United Kingdom. We aimed to identify any trends in drug‐related deaths associated with vaping product use in the United Kingdom. Methods: We retrospectively identified any deaths associated with the use of vaping products reported to the UK National Programme on Substance Abuse Deaths (NPSAD). This contains voluntarily reported information from UK Coroners on more than 42 000 deaths related to psychoactive drugs, other than nicotine or caffeine, which occurred between 1997 and 2020. Results: Two drug‐related deaths were reported which were associated with vaping products, one person having died in 2017 and one in 2018. Both decedents were men currently serving prison sentences in England and were aged 26 and 42 years at the time of death. Both deaths were associated with recent use of Synthetic Cannabinoid Receptor Agonists (SCRAs), with no other substances found to be implicated in death. No details regarding the type of vaping products were available. Conclusions: In a UK sample (1997 to 2020) of 42 000 deaths related to psychoactive drugs other than nicotine or caffeine, only two deaths were associated with vaping products, and those involved use of synthetic cannabinoid receptor agonists.